AGC Biologics Enters into a Manufacturing Service Agreement with Medigene for TCR Therapy

Published: October 2023

On 25 October 2023, AGC Biologics, a contract development and manufacturing organization (CDMO), signed a manufacturing service agreement with Medigene for the production of MDG1015, an autologous TCR cell therapy, focused on the treatment of solid cancers. MDG1015 is currently in the pre-clinical phase of development. AGC Biologics will perform a process transfer and clinical manufacturing of Medigene’s product candidate at its Cell and Gene Center of Excellence in Milan. As per Selwyn Ho, CEO at Medigene, this is agreement is the critical first step in ensuring that their lead product candidate MDG1015 is ready for GMP clinical evaluation

According to Roots Analysis, the TCR therapy market is estimated to be worth $0.03 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 51% during the forecast period, mainly driven by the need for targeted cancer treatment for solid tumors.

For detailed insights about this domain, check out our report on TCR therapy market or email

You may also be interested in the following titles: 

  1. T-Cell Therapy Market, 2022-2035
  2. CAR T Cell Market, 2022-2035
  3. Treg Therapy Market, 2021-2035


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry